A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Boehringer Ingelheim
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
AstraZeneca
Wake Forest University Health Sciences
Regeneron Pharmaceuticals
Big Ten Cancer Research Consortium
Inhibrx Biosciences, Inc
Merck Sharp & Dohme LLC
Fundación GECP
Massachusetts General Hospital